Definium Therapeutics is trading at $46.24 (-4.57%) as the stock undergoes a technical pullback following a sharp +6.91% gain on July 9.
- The recent price action follows a significant rally triggered by June 22’s positive Phase 3 Emerge results for DT120 in major depressive disorder and a subsequent $700 million capital raise.
- No new company-specific catalysts were reported today; the decline appears to be a period of stabilization as the broader market remains mixed and the Nasdaq trades slightly lower.